Onco-innovations Ltd. Stock
€0.77
Your prediction
Financial data and news for Onco-innovations Ltd.
sharewise wants to provide you with the best news and tools for Onco-innovations Ltd., so we directly link to the best financial data sources.
Financials
News
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Also Announces Extension of IR Program
Vancouver, Canada – May 1, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Vancouver, Canada – April 28, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announced, further to its news release
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Vancouver, Canada – April 23, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it has
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Vancouver, Canada – April 21, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces the successful completion of a
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Company also announces Marketing Engagement
Vancouver, Canada – April 7, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company
Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
Vancouver, Canada – February 4, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) announces that it has filed a
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
Vancouver, Canada – December 07, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco” or the “Company”) is pleased to announce that it has
Onco-Innovations Attends University of Alberta’s 2025 Innovation Awards
Vancouver, Canada – November 25, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that it was
Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
Vancouver, Canada – November 20, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that its
Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
Vancouver, Canada – November 18, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company”) is pleased to announce that it is
Onco-Innovations’ Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
Vancouver, Canada – November 7, 2025 – Onco-Innovations Limited (CBOE CA: ONCO) (Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco" or the "Company") is pleased to announce that its